Summary of Significant Accounting Policies - Schedule of Company Revenue and Adjusted EBITDA by Segment (Details) - USD ($) $ in Thousands		3 Months Ended
		Jun. 30, 2022	Jun. 30, 2021
Segment Revenue
Total Revenue	[1]	$ 64,513	$ 59,239
Segment Adjusted EBITDA
Total Adjusted EBITDA		(49,715)	(27,275)
Net income (loss)		(89,532)	(42,026)
Adjustments
Interest (income) expense, net		(245)	(44)
Other income (expense), net		435	(14)
Change in fair value of warrant liabilities		0	534
Benefit from income taxes		254	0
Depreciation and Amortization		5,104	4,638
Amortization Of Acquired Intangible Assets		4,315
Stock-based compensation expense		30,462	9,637
Total Adjusted EBITDA		(49,715)	(27,275)
Consumer And Research Services [Member]
Segment Revenue
Total Revenue		64,513	59,239
Segment Adjusted EBITDA
Total Adjusted EBITDA		(16,997)	(505)
Therapeutics
Segment Adjusted EBITDA
Total Adjusted EBITDA		(18,465)	(18,303)
Unallocated Corporate [Member]
Segment Adjusted EBITDA
Total Adjusted EBITDA	[1]	$ (14,253)	$ (8,467)

[1] There was no Therapeutics revenue for the three months ended June 30, 2022 and 2021.